Does Blue Cross Blue Shield of Michigan Cover Prolia?

How BCBSM Classifies Prolia for Coverage

Blue Cross Blue Shield of Michigan processes Prolia claims under the medical benefit, not the pharmacy benefit. This matters. Because denosumab is a physician-administered subcutaneous injection given every six months, it falls under Part B-style medical coverage for most BCBSM commercial and Medicare Advantage plans. The distinction affects cost-sharing: medical benefit copays follow your plan's office-visit or outpatient-procedure structure rather than a tiered drug formulary.

BCBSM commercial PPO and HMO plans both include Prolia in their specialty drug coverage policies, though each requires prior authorization before the first dose [1]. Medicare Advantage plans administered by BCBSM follow CMS National Coverage Determination guidelines, which have covered denosumab for osteoporosis since the drug's FDA approval in 2010 [2]. Blue Care Network (BCN), the HMO subsidiary of BCBSM, maintains a separate prior authorization form but applies nearly identical clinical criteria.

For members enrolled in BCBSM's self-funded employer group plans, coverage can vary because employers customize their benefit packages. Roughly 60% of BCBSM's commercial membership is in self-funded arrangements, so checking your specific Summary of Benefits and Coverage document is a necessary first step [3].

Prior Authorization Requirements

BCBSM requires prior authorization for every Prolia prescription. The insurer will not reimburse claims submitted without an approved authorization on file. Approval typically depends on meeting all of the following criteria, as outlined in BCBSM's medical policy for denosumab.

Clinical criteria for approval:

• A confirmed diagnosis of osteoporosis based on a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip [4]
• OR a history of fragility fracture consistent with osteoporotic bone disease
• OR a FRAX 10-year probability of major osteoporotic fracture exceeding 20% or hip fracture exceeding 3% [5]
• Documented trial and failure, intolerance, or contraindication to at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for a minimum of 3 months)
• Serum calcium and 25-hydroxyvitamin D levels checked within 90 days of the authorization request
• Adequate calcium (at least 1 to 000 mg daily) and vitamin D (at least 800 IU daily) supplementation documented in the chart

The authorization is typically granted for 12 months, covering two injections. Reauthorization requires updated documentation showing continued medical necessity, including a repeat DXA scan if the prior scan is older than two years.

Denials most commonly occur when the prescribing physician omits documentation of a bisphosphonate trial. According to a 2023 analysis of commercial insurer denials for osteoporosis biologics, step therapy documentation gaps accounted for 41% of initial prior authorization rejections across major carriers [6].

What You Will Pay Out of Pocket

The actual cost of Prolia without any insurance coverage runs between $1,800 and $2,200 per injection based on 2025 Average Wholesale Price data [7]. With BCBSM coverage, your share depends on your plan type and where you fall relative to your annual deductible.

Commercial PPO plans: After meeting your deductible, most BCBSM PPO members pay 20% coinsurance for outpatient specialty services. That translates to roughly $360 to $440 per injection until you reach your out-of-pocket maximum. Some employer-sponsored plans apply flat copays of $50 to $150 instead.

Blue Care Network HMO plans: BCN members typically pay a fixed specialist office visit copay ($30 to $75) that includes the injection when administered in the physician's office. If administered in a hospital outpatient facility, a separate facility copay may apply.

BCBSM Medicare Advantage (Medicare Plus Blue): Members pay 20% of the Medicare-approved amount after the Part B deductible ($257 in 2025). For most members, this means $50 to $90 per injection. Some Medicare Plus Blue PPO plans cap specialist copays at $40 for in-network providers.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (RR 0.32 to 95% CI 0.26 to 0.41) and hip fractures by 40% (RR 0.60 to 95% CI 0.37 to 0.97) over 36 months compared to placebo [8]. These efficacy data are central to why insurers, including BCBSM, classify denosumab as medically necessary for patients meeting diagnostic thresholds.

Step Therapy: The Bisphosphonate-First Rule

BCBSM's step therapy policy requires patients to try an oral bisphosphonate before Prolia will be authorized. This is consistent with the American Association of Clinical Endocrinologists (AACE) 2020 guidelines, which recommend alendronate or risedronate as first-line pharmacotherapy for most patients with osteoporosis [9].

Exceptions exist. BCBSM will approve Prolia as a first-line agent when the patient has:

• Documented esophageal disorders (stricture, achalasia, Barrett's esophagus) that contraindicate oral bisphosphonates
• Inability to remain upright for 30 minutes after dosing
• Chronic kidney Disease with eGFR <35 mL/min/1.73 m², where bisphosphonates are contraindicated [10]
• Active upper GI bleeding or a history of bisphosphonate-related esophageal ulceration
• Very high fracture risk (T-score <-3.0, or multiple vertebral fractures), where AACE guidelines recommend initial treatment with an anabolic agent or denosumab

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and principal investigator of the FREEDOM trial, has noted: "For patients with very high fracture risk, starting with a potent antiresorptive like denosumab rather than waiting for a bisphosphonate to fail can prevent fractures that would otherwise occur during that trial period" [8].

If your physician believes step therapy should be bypassed, a letter of medical necessity documenting the specific contraindication or clinical rationale can be submitted alongside the prior authorization request. BCBSM's own policy documents indicate that step therapy exceptions are reviewed within 72 hours of submission for urgent cases.

Coverage for Non-Osteoporosis Indications

Prolia carries FDA approval for several indications beyond postmenopausal osteoporosis. BCBSM's coverage extends to these uses, though each requires its own prior authorization with indication-specific documentation.

Glucocorticoid-induced osteoporosis (GIOP): Covered when the patient has been on prednisone 7.5 mg/day or equivalent for 3 or more months and meets T-score criteria. The ACR 2022 guidelines for GIOP management recommend denosumab as a second-line option after oral bisphosphonates [11].

Androgen deprivation therapy bone loss: Men receiving androgen deprivation therapy for nonmetastatic prostate cancer are eligible. The ADAMO trial (N=1,468) showed denosumab increased lumbar spine BMD by 5.6% at 24 months in this population [12]. BCBSM requires documentation of the cancer diagnosis and ongoing ADT.

Aromatase inhibitor-associated bone loss: Women receiving adjuvant aromatase inhibitor therapy for breast cancer qualify under the same policy. The ABCSG-18 trial (N=3,425) demonstrated that denosumab reduced clinical fractures by 50% (HR 0.50 to 95% CI 0.39 to 0.65) in women on aromatase inhibitors [13].

Male osteoporosis: BCBSM covers Prolia for men with primary osteoporosis confirmed by DXA, applying the same T-score and step therapy requirements as for postmenopausal women. The ADAMO study provides the efficacy basis for this indication [12].

BCBSM does not cover Prolia for the treatment of bone metastases. That indication requires Xgeva (denosumab 120 mg), which is a separate product with its own coverage policy.

How to File and Appeal a Claim

When Prolia is administered in a physician's office or outpatient infusion center, the provider bills BCBSM directly using HCPCS code J0897 (denosumab injection, 1 mg) with 60 units. The claim is processed under your medical benefit. In most cases, your provider's billing staff handles submission.

If your claim is denied, BCBSM offers a structured appeals process:

1. Internal appeal (Level 1): Submit within 180 days of the denial. Include the Explanation of Benefits, a letter from the prescribing physician explaining medical necessity, supporting lab work (DXA, calcium, vitamin D levels), and documentation of bisphosphonate trial results. BCBSM must respond within 30 days for a standard appeal or 72 hours for an expedited appeal involving urgent medical need.

2. External review: If the internal appeal is denied, Michigan law (PA 251 of 2000) entitles you to an independent external review through a certified Independent Review Organization (IRO). The IRO's decision is binding on BCBSM. The Michigan Department of Insurance and Financial Services (DIFS) oversees this process.

According to the Kaiser Family Foundation's 2024 analysis of insurer appeal outcomes, external reviews for specialty drug denials are overturned in favor of the patient approximately 45% of the time nationwide [14].

Reducing Your Out-of-Pocket Cost

Several programs can lower what you pay for Prolia under BCBSM coverage.

Amgen FIRST STEP Program: Commercially insured patients (not Medicare or Medicaid) may be eligible for a copay card that reduces out-of-pocket costs to as low as $0 per injection for up to 24 months. The program covers up to $1 to 500 in copay or coinsurance per injection [15].

Amgen Safety Net Foundation: Uninsured or underinsured patients earning below 400% of the Federal Poverty Level ($62,400 for a single individual in 2025) can receive Prolia at no cost through this patient assistance program.

BCBSM case management referral: Members with high out-of-pocket costs can request a case manager through BCBSM's customer service line. Case managers can identify whether your plan has an out-of-pocket maximum accumulator or copay accumulator program that affects how manufacturer assistance is applied to your deductible.

One important detail for 2025 and 2026: some BCBSM employer group plans have adopted copay accumulator adjustment programs that prevent manufacturer copay card payments from counting toward your annual deductible or out-of-pocket maximum. If your plan uses an accumulator, the Amgen copay card still reduces your immediate cost per injection but does not help you reach your deductible faster. Ask your HR benefits coordinator or call the number on your BCBSM card to confirm whether your plan uses this structure.

What Happens if You Stop Prolia

Coverage questions are practical, but so is this clinical warning. Discontinuing denosumab without transitioning to another antiresorptive therapy causes rapid bone density loss and a documented rebound increase in vertebral fracture risk. A 2017 analysis in the Journal of Clinical Endocrinology & Metabolism found that patients who stopped denosumab without follow-on therapy experienced vertebral fracture rates of 7.1% within 12 months, compared to 0.8% in those who transitioned to a bisphosphonate [16].

The Endocrine Society's 2024 clinical practice guideline recommends that patients who discontinue denosumab receive at least one infusion of zoledronic acid (5 mg IV) or 12 months of oral alendronate beginning 6 months after the last Prolia dose [17]. BCBSM covers zoledronic acid infusion under the medical benefit, and oral alendronate is a Tier 1 generic on all BCBSM pharmacy formularies at $0 to $10 per month.

This means that maintaining continuous BCBSM coverage during Prolia treatment is clinically significant. A gap in insurance that causes a missed dose can create a rebound fracture window. If you are changing jobs, aging into Medicare, or transitioning between BCBSM plans, coordinate with your physician to ensure no treatment gap exceeds 7 months from the last injection.

Michigan-Specific Considerations

Michigan has a state insurance mandate (MCL 500.3406s) requiring that health insurers cover FDA-approved drugs for conditions included in the policy's disease coverage. Since osteoporosis treatment is a standard covered condition in all BCBSM plans sold in Michigan, Prolia cannot be categorically excluded from the formulary. The mandate does not prevent step therapy or prior authorization requirements, but it does prevent blanket denial of the drug class.

Michigan's Medicaid program (Healthy Michigan Plan) also covers Prolia, though it uses a different prior authorization pathway administered through the Michigan Department of Health and Human Services pharmacy benefit manager, Magellan Rx Management. Dual-eligible patients (those with both BCBSM Medicare Advantage and Medicaid) should confirm which benefit is primary to avoid claim coordination delays.

The 2024 Michigan Osteoporosis Action Plan, released by the Michigan Department of Health and Human Services, reported that approximately 540,000 Michigan residents over age 50 have osteoporosis, yet fewer than 25% of those diagnosed receive any pharmacologic treatment [18]. Insurance coverage barriers, including prior authorization complexity, contribute to this treatment gap.

As Dr. Ethel Siris, professor of medicine at Columbia University and past president of the National Osteoporosis Foundation, stated in a 2023 JBMR editorial: "The prior authorization burden for osteoporosis medications is disproportionate to the clinical risk of the drugs and contributes measurably to the osteoporosis treatment gap in the United States" [19].

Comparing Prolia Coverage to Alternative Osteoporosis Drugs on BCBSM

Not all osteoporosis medications face the same coverage hurdles with BCBSM. Here is how Prolia compares to other options.

Alendronate (Fosamax generic): Tier 1 generic, no prior authorization, $0 to $10/month. First-line per BCBSM step therapy.

Risedronate (Actonel generic): Tier 1 or 2 generic, no prior authorization, $5 to $20/month.

Zoledronic acid (Reclast generic): Medical benefit, prior authorization required but step therapy is sometimes waived for patients who cannot tolerate oral medications. Copay: $100 to $300 per annual infusion.

Teriparatide (Forteo): Specialty pharmacy benefit, Tier 5, prior authorization required. Copay: $200 to $600/month. Restricted to patients with very high fracture risk per BCBSM policy.

Romosozumab (Evenity): Medical benefit, prior authorization required with more stringent criteria than Prolia. Limited to 12 monthly doses. Copay: $300 to $800/month. BCBSM requires T-score <-3.0 or multiple fractures plus bisphosphonate failure.

Abaloparatide (Tymlos): Specialty pharmacy benefit, Tier 5, prior authorization required. Copay: $200 to $500/month. Similar restrictions to teriparatide.

For patients with commercial BCBSM coverage who have already tried and failed a bisphosphonate, Prolia typically represents the most accessible next-step option in terms of both authorization approval rates and patient cost after manufacturer copay assistance.